CPL-M3-RTA 10mg (Metabolic Research)
Original price was: $ 124.00.$ 99.00Current price is: $ 99.00.
Three Receptors. One Peptide. Early Research.
Retatrutide is the first triple agonist — simultaneously activating GIP, GLP-1, and glucagon receptors. Published in NEJM 2023, it represents the cutting edge of multi-receptor metabolic research.
Why Researchers Study It
- Triple agonism — GIP + GLP-1 + glucagon receptors
- NEJM 2023 Phase 2 data — dose-dependent effects on body composition
- Glucagon receptor — adds energy expenditure and lipid oxidation signaling
- Three generations — semaglutide (1 receptor) → tirzepatide (2) → retatrutide (3)
What Makes It Different
Adding the glucagon receptor to the incretin mix is what makes retatrutide unique. Glucagon signaling contributes energy expenditure and lipid oxidation — mechanisms that GLP-1 and GIP alone don’t address.
Analytical Documentation
- Purity: Batch-specific Certificate of Analysis (COA) included
- Method: HPLC and/or LC-MS verification
- Storage: Lyophilized — store cool, dry, protected from light
⚠️ For research use only. Not for human consumption. Not for therapeutic, diagnostic, or veterinary application. Researchers are responsible for compliance with applicable regulations.
Choice Peptide Labs – Certificate of Analysis
Product: Retatrutide
Strength: 10mg
Batch / Lot: PB-2026-RET-0067
COA Date: Apr 10, 2026
Product Information
Testing laboratory / source: Data derived from supplier COA (Aodt Peptides)
Appearance: White lyophilized powder
Storage: -20°C, dry, dark
Analytical Results
Purity: 99.2%
Analytical method: RP-HPLC / ESI-MS
Result summary: Purity meets or exceeds internal specification for research use.
Conform/Pass: BATCH RELEASED — All tests conform to specifications
Notes
This certificate summarizes analytical data provided by the original testing laboratory. Minor
formatting or language changes have been made for consistency.
Disclaimer
For laboratory research use only. Not for human or animal consumption. No therapeutic or
diagnostic use.
